NTP-PAROXETINE 30 MG
PAROXETINE (PAROXETINE HYDROCHLORIDE ACETONE SOLVATE) : 30 MG · DIN 02382520 · TEVA CANADA LIMITED
Health Canada status: CANCELLED PRE MARKET
What is NTP-PAROXETINE?
NTP-PAROXETINE 30 MG contains PAROXETINE (PAROXETINE HYDROCHLORIDE ACETONE SOLVATE) : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02382520, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 17-Mar-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NTP-PAROXETINE used for?
Symptomatic relief of Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Social Phobia (Social Anxiety Disorder), Generalized Anxiety Disorder, and Posttraumatic Stress Disorder.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02382520 |
|---|---|
| Brand name | NTP-PAROXETINE |
| Generic / active ingredient | PAROXETINE (PAROXETINE HYDROCHLORIDE ACETONE SOLVATE) : 30 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 30 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AB05 PAROXETINE |
| AHFS class | 48:10.24 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 17-Mar-2016 |
| Original market date | 2012-06-10 00:00:00 |
How is it administered?
Administered once daily, usually in the morning with food. Dosage varies by indication (Depression: 20mg; OCD/Panic: 40mg). Gradual dose reduction is recommended for discontinuation.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refers to Storage and Stability section).
How is it supplied?
Not explicitly detailed in provided text (refers to Dosage Forms, Composition and Packaging section).
Contraindications
Hypersensitivity; Concomitant use with MAO inhibitors (or within 2 weeks of use); Concomitant use with Thioridazine; Concomitant use with Pimozide.
Warnings and precautions
Potential association with behavioural/emotional changes including self-harm; risk of discontinuation symptoms; Serotonin Syndrome; abnormal bleeding; hyponatremia; seizures.
What can be used instead?
Other Canadian products sharing ATC code N06AB05 PAROXETINE. 51 of 106 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-PAROXETINE TABLETS | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510480 |
| AG-PAROXETINE TABLETS | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510499 |
| AG-PAROXETINE TABLETS | 30 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510510 |
| APO-PAROXETINE | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02240907 |
| APO-PAROXETINE | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02240908 |
| APO-PAROXETINE | 30 MG | TABLET | APOTEX INC | MARKETED | DIN 02240909 |
| AURO-PAROXETINE | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02383276 |
| AURO-PAROXETINE | 20 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02383284 |
| AURO-PAROXETINE | 30 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02383292 |
| BIO-PAROXETINE | 10 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02444909 |
Who else supplies PAROXETINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PAROXETINE appears in 4233 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.